Business Wire
17 Mar 2026, 20:44 UTC · 26w ago
Verdict
Headline takes no side. We score VSTM +0.50 across one claim — strongly bullish.
+0.50strongly bullish
More positive than 64% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Verastem Oncology will present new long-term Phase 2 RAMP 201 clinical trial data for the AVMAPKI FAKZYNJA combination therapy at the SGO 2026 Annual Meeting.
So whatNew clinical trial data for a lead combination therapy is a primary catalyst for biotech valuation and investor sentiment.
More positive than 76% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 64% of ticker scores this week
The company announced it will present new long-term clinical trial data for its combination therapy at a major medical meeting.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+40.9%
Price agrees with the score
$7.99 vs $5.67 close before publication (Mar 17) · not market-adjusted
VSTM chart →